Stock Ratings / Health Care / INBX / dividends

IMTX (52) CGEM (36) ODTX (59) PRME (21) ⌘ Pro Terminal →

Inhibrx Biosciences Inc. (INBX) Dividend Safety Gauge & 10-Year DRIP Compounder

Q: Does INBX pay a dividend and is it safe?

Inhibrx Biosciences Inc. (INBX) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

$73.65 +0.49% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Inhibrx Biosciences Inc. (INBX) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $1.08B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-12.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for INBX)Realized 20D OHLCV Swing Band: ±12.5%

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (15.1% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $40,809

Est. Year-10 Shareholder Yield: $245/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$11.5K

Yr 1

$13.2K

Yr 2

$15.2K

Yr 3

$17.6K

Yr 4

$20.2K

Yr 5

$23.3K

Yr 6

$26.8K

Yr 7

$30.8K

Yr 8

$35.5K

Yr 9

$40.8K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring INBX)

✓Walkthrough of INBX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

INBX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -43.00%📐 HORIZONTAL RANGE

2026-10-30O $72.04H $73.65L $66.80C $73.65VOL 438.8K

RES: $162.0SUP: $62.87SMA50: $102.3SMA200: $92.14

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

INBX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 INBX Butterfly Map → + Track INBX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on INBX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for INBX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for INBX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (INBX)

Health Care Rank #911 of 1016 ⚔️ IMTX vs INBX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (INBX vs. IMTX, CGEM, ODTX, PRME)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Inhibrx Biosciences Inc. (INBX) ranks #911 by composite RQD confidence (31/100, grade E) and #355 by equity capitalization ($1.08B). Within this direct 5-issuer industry benchmark cohort, INBX leads on earnings valuation at N/A trailing P/E, while INBX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. ODTX currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with INBX at 31/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
INBX ACTIVE Inhibrx Biosciences Inc.	E	31/100	—	—	-35.0%	+0.49%	$1.08B	Benchmark Subject
IMTX Immatics N.V.	D+	52/100	—	—	—	-0.54%	$1.09B	/imtx-vs-inbx →
CGEM Cullinan Therapeutics Inc.	D-	36/100	—	—	-35.0%	-0.71%	$994.3M	/cgem-vs-inbx →
ODTX Odyssey Therapeutics Inc.	C-	59/100	—	—	—	+1.48%	$953.0M	/odtx-vs-inbx →
PRME Prime Medicine Inc.	E	21/100	—	—	-35.0%	-2.24%	$950.4M	/prme-vs-inbx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002007919

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Inhibrx Biosciences Inc. (INBX) reported GAAP revenue of $1.3M (+550.0% vs. FY2024 revenue of $200.0K , and -27.8% cumulative change since FY2023) , GAAP net income of -$140.1M, operating cash flow of -$129.8M, and free cash flow of -$129.8M (+34.1% YoY). On the balance sheet, INBX closed FY2025 with $146.5M in total assets against $100.6M in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$1.3M	-$140.1M	-$129.8M	-$129.8M	$146.5M	$100.6M
FY2024 (FY)	2024-12-31	$200.0K	$1.69B	-$194.4M	-$197.0M	$180.8M	$0
FY2023 (FY)	2023-12-31	$1.8M	-$241.4M	-$193.3M	-$193.3M	—	—

3. INBX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is INBX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Inhibrx Biosciences Inc. (NASDAQ: INBX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $73.65 (+0.49% 1D, market cap $1.08B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 3/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, INBX ranks #911 in composite RQD confidence.

How does INBX compare to IMTX and CGEM in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), INBX carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IMTX (Immatics N.V.) holds a D+ grade (52/100 RQD, P/E N/A, ROIC —, cap $1.09B) and CGEM (Cullinan Therapeutics Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $994.3M). Among the 5-stock peer group, INBX leads on earnings multiple (N/A) while INBX leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for INBX?

Per INBX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002007919), Inhibrx Biosciences Inc. generated $1.3M in revenue (+550.0% YoY), -$140.1M in net income, and -$129.8M in free cash flow against $146.5M in total assets and $100.6M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is INBX trading relative to its 50-day, 200-day, and 52-week technical levels?

INBX last traded at $73.65 (+0.49% on volume of 358,799 shares), positioning the stock -28.03% below its 50-day simple moving average ($102.34) and -20.07% below its 200-day simple moving average ($92.14). Across its 52-week range of $57.30 to $155.29, INBX sits at the 16.7% percentile with a 14-day RSI of 31.2 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($64.44 to $82.86).

INBX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does INBX pay a dividend and is it safe?

Inhibrx Biosciences Inc. (INBX) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: INBX RQD Cockpit INBX 12M Forecast INBX Earnings & Move INBX Dividends & DRIP INBX Insiders & 13F INBX Whale Options INBX Profit Sankey INBX News & Why